<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03413137</url>
  </required_header>
  <id_info>
    <org_study_id>0618-17-RMC</org_study_id>
    <nct_id>NCT03413137</nct_id>
  </id_info>
  <brief_title>Comparing Transperineal to Transrectal MRI-US Fusion Prostate Biopsy</brief_title>
  <official_title>A Prospective Cohort Study Comparing Transperineal to Transrectal MRI-US Fusion Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rabin Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rabin Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This will be a prospective cohort trial that compares transperineal to transrectal MRI-US
      fusion prostate biopsy
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a prospective cohort trial that compares transperineal to transrectal MRI-US
      fusion prostate biopsy among men. The target population are males that are schedule to
      undergo MRI-US Fusion prostate biopsy and have an MRI of the prostate. All the pathological
      samples would be conducted from the area in the prostate that was found as suspicious of
      malignancy by previous MRI imaging, and defined as region of interest (ROI).

      First the prostate biopsy will be preformed in a transperineal approach; Then a transrectal
      approach would be used to sample a few more cores.

      The primary endpoint will be To compare the detection rate for clinically significant
      prostate cancer between transperineal vs transrectal mp-MRI-fusion/TRUS biopsies.
      Additionally, the study aims to determine the accuracy of prostate cancer detection in
      transperineal vs transrectal mp-MRI-fusion/TRUS biopsies.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">December 11, 2017</start_date>
  <completion_date type="Anticipated">October 2019</completion_date>
  <primary_completion_date type="Anticipated">October 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Using the NaviGo™ system each patient will undergo a biopsy using the transperineal followed by transrectal approach.</intervention_model_description>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Detection rate for clinically significant prostate cancer</measure>
    <time_frame>within 2 years</time_frame>
    <description>To compare the detection rate for clinically significant prostate cancer between transperineal vs transrectal mp-MRI-fusion/TRUS biopsies.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of cores positive per region of interest (ROI)</measure>
    <time_frame>within 2 years</time_frame>
    <description>To determine the accuracy of prostate cancer detection in transperineal vs transrectal mp-MRI-fusion/TRUS biopsies - Percentage of cores positive per region of interest (ROI)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of volume of cores positive per region of interest (ROI)</measure>
    <time_frame>within 2 years</time_frame>
    <description>To determine the accuracy of prostate cancer detection in transperineal vs transrectal mp-MRI-fusion/TRUS biopsies - Amount of volume of cores positive per region of interest (ROI)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">76</enrollment>
  <condition>Prostate Biopsy</condition>
  <arm_group>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A Transperineal mpMRI-US Fusion prostate biopsy followed by a Transrectal mpMRI-US Fusion prostate biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>A Transrectal mpMRI-US Fusion prostate biopsy followed by a Transperineal mpMRI-US Fusion prostate biopsy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transperineal mpMRI-US Fusion prostate biopsy</intervention_name>
    <description>mpMRI-US Fusion prostate biopsy in a transperineal approach to direct the needles towards an area in the prostate that was found as suspicious of malignancy by previous MRI imaging, defined as region of interest (ROI).</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>MRI-US Fusion TP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Transrectal mpMRI-US Fusion prostate biopsy</intervention_name>
    <description>using the same system and MRI imaging, a transrectal approach would be used to sample a few more cores from the ROI as defined by the MRI imaging.</description>
    <arm_group_label>Arm A</arm_group_label>
    <arm_group_label>Arm B</arm_group_label>
    <other_name>MRI-US Fusion TR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Men who are scheduled to undergo, transrectal or transperineal biopsy and have an MRI
             of the prostate.

             • Either primary biopsy or repeated biopsy

          2. Age 18-90.

          3. PI-RADS classification of 3-5

        Exclusion Criteria:

          1. Men who do not have an MRI of the prostate.

          2. PI-RADS classification of 2 or lower

          3. Men who were diagnosed with prostate cancer and have begun treatment
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>David Margel, MD PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Rabn Medical Center, Beilinson Campus</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sivan Sela, B.Sc</last_name>
    <phone>+972(0)3-9376553</phone>
    <email>Sivanto1@clalit.org.il</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Tzlil Tabachnik, M.Sc</last_name>
    <phone>+972(0)3-9376553</phone>
    <email>Tzlilta1@clalit.org.il</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Rabin Medical Center, Beilinson campus</name>
      <address>
        <city>Petach Tikva</city>
        <zip>4941492</zip>
        <country>Israel</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sivan Sela, B.Sc</last_name>
      <phone>+972-3-9376553</phone>
      <email>Sivanto1@clalit.org.il</email>
    </contact>
    <contact_backup>
      <last_name>Tzlil Tabachnik, M.Sc</last_name>
      <phone>+972-3-9376553</phone>
      <email>Tzlilba1@clalit.org.il</email>
    </contact_backup>
    <investigator>
      <last_name>David Margel, MD PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jack Baniel, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Kedar, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Daniel Halstuch, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 15, 2017</study_first_submitted>
  <study_first_submitted_qc>January 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 29, 2018</study_first_posted>
  <last_update_submitted>January 28, 2018</last_update_submitted>
  <last_update_submitted_qc>January 28, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 30, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prostate cancer</keyword>
  <keyword>transperineal mp-MRI-fusion/TRUS biopsies</keyword>
  <keyword>mp-MRI fusion/TRUS transrectal biopsy</keyword>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

